BLFS vs. NARI, PRCT, NVST, IRTC, NVCR, LIVN, ENOV, WRBY, TNDM, and TMDX
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), iRhythm Technologies (IRTC), NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry.
BioLife Solutions vs.
Inari Medical (NASDAQ:NARI) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.
Inari Medical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.
Inari Medical has a net margin of -13.68% compared to BioLife Solutions' net margin of -38.98%. BioLife Solutions' return on equity of -6.61% beat Inari Medical's return on equity.
BioLife Solutions received 245 more outperform votes than Inari Medical when rated by MarketBeat users. Likewise, 67.46% of users gave BioLife Solutions an outperform vote while only 57.89% of users gave Inari Medical an outperform vote.
91.0% of Inari Medical shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 10.6% of Inari Medical shares are owned by company insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Inari Medical presently has a consensus target price of $68.00, indicating a potential downside of 14.52%. BioLife Solutions has a consensus target price of $29.43, indicating a potential upside of 12.58%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Inari Medical.
Inari Medical has higher revenue and earnings than BioLife Solutions. Inari Medical is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioLife Solutions had 4 more articles in the media than Inari Medical. MarketBeat recorded 6 mentions for BioLife Solutions and 2 mentions for Inari Medical. BioLife Solutions' average media sentiment score of 0.18 beat Inari Medical's score of 0.06 indicating that BioLife Solutions is being referred to more favorably in the news media.
Summary
BioLife Solutions beats Inari Medical on 12 of the 17 factors compared between the two stocks.
Get BioLife Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
Related Companies and Tools
This page (NASDAQ:BLFS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free BLFS Stock Alerts